Latest Biotech News

Researchers from the University of Oxford deployed artificial intelligence techniques alongside high-resolution satellite imagery to reassess wildebeest populations during the Great Migration in...

Swedish biopharmaceutical company Alzinova received FDA approval to commence Phase II clinical trials for ALZ-101, a therapeutic vaccine targeting toxic amyloid-beta oligomers implicated in...

Novartis announced the acquisition of Tourmaline Bio for $1.4 billion, obtaining exclusive rights to an anti-inflammatory heart medication nearing Phase 3 trials. The deal is set to bolster...

Rapport Therapeutics reported positive topline Phase II data for RAP-219, a TARPγ8-specific AMPAR negative allosteric modulator for focal onset seizures. The drug reduced clinical seizure...

Recent data from the 2025 World Conference on Lung Cancer have highlighted advances and challenges in the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)....

Eli Lilly launched TuneLab, a platform granting small biotech firms access to Lilly’s extensive AI models trained on decades of internal data, focusing on small-molecule drug properties and...

VedaBio secured a non-exclusive license from Mammoth Biosciences for its CRISPR-based diagnostic technologies, aiming to enhance its amplification-free diagnostic platform. The collaboration...

Alzinova announced FDA approval of its Investigational New Drug application for ALZ-101, a novel vaccine targeting toxic amyloid-beta oligomers implicated in Alzheimer’s disease. Following...

Belgian bioinformatics startup Aspect Analytics closed a €10 million ($11.7 million) Series A round led by PMV and Capricorn Partners to expand its cloud-based Weave platform. The platform...

NRG Therapeutics Ltd., backed by investors including Merck KGaA and Novartis, completed an oversubscribed £50 million (US$67 million) Series B financing. The company plans to progress its novel...

BioAtla announced results from its FDA Type B (End of Phase 2) meeting regarding the clinical development plan for ozuriftamab vedotin in oropharyngeal squamous cell carcinoma. The productive...

David Baltimore, a towering figure in molecular biology and a Nobel laureate, has passed away at age 87. Renowned for his discovery of reverse transcriptase—a key enzyme in the replication of...

Rapport Therapeutics announced promising mid-stage Phase 2a trial results for RAP-219, a novel drug targeting focal onset seizures. The open-label study demonstrated a median 78% reduction in...

Eli Lilly unveiled TuneLab, an AI platform granting select small biotech firms access to advanced drug discovery models developed from decades of Lilly's research data. The initiative aims to...

Novartis announced a $1.4 billion agreement to acquire Tourmaline Bio, gaining rights to a promising cardiovascular therapy originally developed at Pfizer. This acquisition aims to bolster...

Recent presentations at major lung cancer conferences highlighted multiple therapeutic advances for non-small cell and small cell lung cancer (NSCLC, SCLC). Among key findings, a Phase 2 study...

Innovations in targeted cancer therapies are gaining momentum with major advancements reported in antibody-drug conjugates (ADCs) and novel prodrug designs. Research published on...

Recent funding and strategic partnerships spotlight accelerated progress in gene and cell therapy. Epigenic Therapeutics secured $60 million in Series B financing to propel CRISPR epigenetic...

Artificial intelligence is rapidly reshaping biotechnology, as demonstrated by new models and tools accelerating drug discovery and cellular analysis. A public AI model from MIT predicts long-term...

Servier announced acquisition of KER-0193, an oral small molecule modulator targeting Fragile X syndrome (FXS) from UK biotech Kaerus Bioscience for up to $450 million. The move bolsters Servier’s...